FGFR1 and non-small cell lung carcinoma: A recent study where mesenchymal cell lines derived from biopsies of NSCLC patients who progressed on EGFR TKIs were analysed by whole-genome CRISPR screening, identified FGFR1 as the top target promoting survival of resistant cells to third-generation EGFR TKIs [61].